comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 12:01:45 - browse：57571

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： How CRISPR works, explained in two minutes

WSS

NFL doctors' conflicts of interest could endanger players, report says

Many breast cancer patients receive more radiation than needed

Slovenia has suffered its worst

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

It was time to plan for my old age. If only I could stop crying

leisure time

comprehensive

hotspot

Bright Health sells Medicare Advantage business to Molina

How CRISPR works, explained in two minutes

Supreme Court strikes down use of affirmative action

Pennsylvania man bitten on the head by bear during attack in his garage

Apple is now the first public company to be valued at $3 trillion

Trump used to be more articulate. What could explain the change?

Bright Health sells Medicare Advantage business to Molina

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

How to save PrEP access — and even expand it

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

knowledge

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Paxlovid rebound happens. Why and to whom are still a mystery

Wearables generate powerful data but its not useful to doctors, yet

Election results set back Medicaid expansion plans

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Tuberculosis patients need more than just free medication

entertainment

focus

focus

hotspot